Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$18.45 - $27.14 $1.94 Million - $2.86 Million
105,377 New
105,377 $1.99 Billion
Q4 2022

Feb 14, 2023

BUY
$20.18 - $33.33 $2.17 Million - $3.58 Million
107,514 New
107,514 $2.65 Million
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $164,459 - $351,215
14,202 Added 17.16%
96,949 $1.74 Million
Q2 2022

Aug 15, 2022

SELL
$8.52 - $25.26 $29,198 - $86,566
-3,427 Reduced 3.98%
82,747 $938,000
Q1 2022

May 11, 2022

BUY
$19.89 - $43.18 $20,228 - $43,914
1,017 Added 1.19%
86,174 $1.92 Million
Q4 2021

Feb 11, 2022

SELL
$26.75 - $46.02 $25,091 - $43,166
-938 Reduced 1.09%
85,157 $3.72 Million
Q3 2021

Nov 12, 2021

BUY
$25.18 - $37.81 $653,043 - $980,602
25,935 Added 43.11%
86,095 $2.87 Million
Q2 2021

Aug 11, 2021

BUY
$14.69 - $27.52 $476,866 - $893,354
32,462 Added 117.2%
60,160 $1.66 Million
Q1 2021

May 13, 2021

SELL
$16.27 - $41.26 $1,919 - $4,868
-118 Reduced 0.42%
27,698 $555,000
Q4 2020

Feb 09, 2021

BUY
$15.96 - $50.0 $443,943 - $1.39 Million
27,816 New
27,816 $917,000

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $565M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.